Nevakar’s business model focuses on repositioning and repurposing existing drugs to address unmet needs that are patient and health care system centric. Nevakar’s unique ideation and pipeline development process allows us to accelerate discovery, development and commercial launch.
We call this novel approach NuPharmingTM.
portfolio
Nevakar focuses on two significant markets:
Ophthalmics
Ophthalmics is a large and growing market in which refractive errors are a key driver.
Hospital Injectables
Hospital Injectables is another underserved market presenting significant patient and healthcare system value. Suboptimal products and delivery are key unmet needs in this market.
Our Pipeline
Ophthalmic Products
Product CandidatesTherapeutic Area | Research | Preclinical | Phase I | Phase II | Phase III |
---|---|---|---|---|---|
NVK-002Atropine for Children with Myopia (US & Europe) | Research | Preclinical | Phase I | Phase II | Phase III |
NVK-002Atropine for Children with Myopia (Asia) | Research | Preclinical | Phase I | Phase II | Phase III |
NVK-029Refractive errors I | Research | Preclinical | Phase I | Phase II | Phase III |
NVK-031Refractive errors II | Research | Preclinical | Phase I | Phase II | Phase III |
Hospital Injectables
Product CandidatesTherapeutic Area | Research | Preclinical | Phase I | Phase II | Phase III |
---|---|---|---|---|---|
NVK-009Acute Pain | Research | Preclinical | Phase I | Phase II | Phase III |
NVK-006Anti-infective | Research | Preclinical | Phase I | Phase II | Phase III |
Critical Care Injectables
Product CandidatesTherapeutic Area | Research | Preclinical | Phase I | Phase II | Phase III |
---|---|---|---|---|---|
NVK-003Anesthesia | Research | Preclinical | Phase I | Phase II | Phase III |
NVK-014Cardiovascular | Approved | ||||
NVK-004Cardiovascular | Research | Preclinical | Phase I | Phase II | Phase III |
NVK-019Cardiovascular | Research | Preclinical | Phase I | Phase II | Phase III |
NVK-005Oncology | Research | Preclinical | Phase I | Phase II | Phase III |
NVK-025Cardiovascular | Research | Preclinical | Phase I | Phase II | Phase III |
NVK-028Cardiovascular | Research | Preclinical | Phase I | Phase II | Phase III |
NVK-030Gastrointestinal | Research | Preclinical | Phase I | Phase II | Phase III |

References for Opthalmics:
1. Fricke TR, Holden BA, Wilson DA, Schlenther G, Naidoo KS, Resnikoff S, et al. Global cost of correcting vision impairment from uncorrected refractive error. Bull World Health Organ 2012;90:728-38. 2. Naidoo KS, Fricke TR, Frick KD, et al. Potential lost productivity resulting from the global burden of myopia: systematic review, meta-analysis, and modeling. Ophthalmology. 2019;126:338–46. 3. World Health Organization Bulletin, 2015;93:667. doi: http://dx.doi.org/10.2471/BLT.15.156844. 4. Fricke TR, Tahhan N, Resnikoff S, Papas E, Burnett A, Ho SM, Naduvilath T, Naidoo KS. Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia: Systematic Review, Meta-analysis, and Modelling. Ophthalmology. 2018 Oct;125(10):1492-1499. doi: 10.1016/j.ophtha.2018.04.013. Epub 2018 May 9. PMID: 29753495.https://www.marketsandmarkets.com/Market-Reports/injectable-drug-delivery-market-150.html
References for Hospital Injectables:
5. https://www.marketsandmarkets.com/Market-Reports/injectable-drug-delivery-market-150.html. 6. Gan TJ et al. Curr Med Res Opin. 2014;30(1):149-160 7.https://patientcarelink.org/improving-patient-care/healthcare-acquired-infections-hais/ 8. https://www.sccm.org/Communications/Critical-Care-Statistics.